LYMPHOMA RESEARCH FOUNDATION — Lobbying Disclosure | Poliscope

LYMPHOMA RESEARCH FOUNDATION

View full entity profile (contributions, contracts, SEC) →

This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.

Lobbying Spend

$268K

Filings

166

Firms Hired

Active Period

2000–2026

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2026	—	3	1
2025	—	4	1
2024	—	4	1
2023	—	7	2
2022	—	8	2
2021	—	8	2
2020	—	9	2
2019	—	8	2
2018	—	8	2
2017	—	8	2
2016	$19,457	9	2
2015	—	8	2
2014	—	10	2
2013	$20,339	9	2
2012	$8,738	9	2
2011	$16,258	8	2
2010	$33,090	9	2
2009	$49,714	9	2
2008	$38,000	8	2
2007	$32,900	6	3
2006	$40,000	3	2
2005	$10,000	4	2
2004	—	1	1
2003	—	2	1
2002	—	1	1
2001	—	2	1
2000	—	1	1

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
LYMPHOMA RESEARCH FOUNDATION	$268,496	77
ROPES & GRAY, LLP	—	8
BENNETT TURNER & COLEMAN LLP	—	3
TURNER & GOSS LLP	—	78

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	77
SENATE	60
Health & Human Services, Dept of (HHS)	1
White House Office	1

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Budget/Appropriations	Budget/Appropriations	45
Health Issues	Health Issues	44
Medicare/Medicaid	Medicare/Medicaid	22
Medical/Disease Research/Clinical Labs	Medical/Disease Research/Clinical Labs	20

Bills Explicitly Cited (25)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 8839119th Congress

Lainie Jones Comprehensive Cancer Survivorship Act of 2026

2026 · third_quarter · Firm: TURNER & GOSS LLP

Open original LDA filing ↗

Cited source text and reported amounts

Lainie Jones Comprehensive Cancer Survivorship Act, HR 8839/S 5052

Client expense: — · Firm income: —

Matched citations: HR 8839

S. 5052119th Congress

Lainie Jones Comprehensive Cancer Survivorship Act of 2026

2026 · third_quarter · Firm: TURNER & GOSS LLP

Open original LDA filing ↗

Cited source text and reported amounts

Lainie Jones Comprehensive Cancer Survivorship Act, HR 8839/S 5052

Client expense: — · Firm income: —

Matched citations: S 5052

H.R. 8839119th Congress

Lainie Jones Comprehensive Cancer Survivorship Act of 2026

2026 · second_quarter · Firm: TURNER & GOSS LLP

Open original LDA filing ↗

Cited source text and reported amounts

Lainie Jones Comprehensive Cancer Survivorship Act, HR 8839

Client expense: — · Firm income: —

Matched citations: HR 8839

H.R. 4364118th Congress

Legislative Branch Appropriations Act, 2024

2024 · second_quarter · Firm: TURNER & GOSS LLP

Open original LDA filing ↗

Cited source text and reported amounts

Comprehensive Cancer Survivorship Act (HR 4364/S 2213)

Client expense: — · Firm income: —

Matched citations: HR 4364

Show 21 more cited filings

S. 2213118th Congress

Comprehensive Cancer Survivorship Act

2024 · second_quarter · Firm: TURNER & GOSS LLP

Open original LDA filing ↗

Cited source text and reported amounts

Comprehensive Cancer Survivorship Act (HR 4364/S 2213)

Client expense: — · Firm income: —

Matched citations: S 2213

H.R. 4364118th Congress

Legislative Branch Appropriations Act, 2024

2024 · first_quarter · Firm: TURNER & GOSS LLP

Open original LDA filing ↗

Cited source text and reported amounts

Comprehensive Cancer Survivorship Act, HR 4364/S2213

Client expense: — · Firm income: —

Matched citations: HR 4364

S. 2213118th Congress

Comprehensive Cancer Survivorship Act

2024 · first_quarter · Firm: TURNER & GOSS LLP

Open original LDA filing ↗

Cited source text and reported amounts

Comprehensive Cancer Survivorship Act, HR 4364/S2213

Client expense: — · Firm income: —

Matched citations: S2213

H.R. 2739114th Congress

Cancer Drug Coverage Parity Act of 2015

2016 · third_quarter · Firm: LYMPHOMA RESEARCH FOUNDATION

Open original LDA filing ↗

Cited source text and reported amounts

Cancer Drug Parity Act of 2015 (H.R. 2739/ S. 1566) Department of Defense Peer Reviewed Cancer Research Program

Client expense: — · Firm income: —

Matched citations: H.R. 2739

S. 1566114th Congress

Cancer Drug Coverage Parity Act of 2015

2016 · third_quarter · Firm: LYMPHOMA RESEARCH FOUNDATION

Open original LDA filing ↗

Cited source text and reported amounts

Cancer Drug Parity Act of 2015 (H.R. 2739/ S. 1566) Department of Defense Peer Reviewed Cancer Research Program

Client expense: — · Firm income: —

Matched citations: S. 1566

H.R. 2739114th Congress

Cancer Drug Coverage Parity Act of 2015

2016 · second_quarter · Firm: LYMPHOMA RESEARCH FOUNDATION

Open original LDA filing ↗

Cited source text and reported amounts

Cancer Drug Parity Act of 2015 (H.R. 2739/ S. 1566) Department of Defense Peer Reviewed Cancer Research Program

Client expense: $6,629 · Firm income: —

Matched citations: H.R. 2739

S. 1566114th Congress

Cancer Drug Coverage Parity Act of 2015

2016 · second_quarter · Firm: LYMPHOMA RESEARCH FOUNDATION

Open original LDA filing ↗

Cited source text and reported amounts

Cancer Drug Parity Act of 2015 (H.R. 2739/ S. 1566) Department of Defense Peer Reviewed Cancer Research Program

Client expense: $6,629 · Firm income: —

Matched citations: S. 1566

H.R. 2739114th Congress

Cancer Drug Coverage Parity Act of 2015

2016 · second_quarter · Firm: LYMPHOMA RESEARCH FOUNDATION

Open original LDA filing ↗

Cited source text and reported amounts

Cancer Drug Parity Act of 2015 (H.R. 2739/ S. 1566) Department of Defense Peer Reviewed Cancer Research Program

Client expense: $6,629 · Firm income: —

Matched citations: H.R. 2739

S. 1566114th Congress

Cancer Drug Coverage Parity Act of 2015

2016 · second_quarter · Firm: LYMPHOMA RESEARCH FOUNDATION

Open original LDA filing ↗

Cited source text and reported amounts

Cancer Drug Parity Act of 2015 (H.R. 2739/ S. 1566) Department of Defense Peer Reviewed Cancer Research Program

Client expense: $6,629 · Firm income: —

Matched citations: S. 1566

H.R. 2739114th Congress

Cancer Drug Coverage Parity Act of 2015

2016 · first_quarter · Firm: LYMPHOMA RESEARCH FOUNDATION

Open original LDA filing ↗

Cited source text and reported amounts

Cancer Drug Parity Act of 2015 (H.R. 2739/ S. 1566) Department of Defense Peer Reviewed Cancer Research Program

Client expense: $6,199 · Firm income: —

Matched citations: H.R. 2739

S. 1566114th Congress

Cancer Drug Coverage Parity Act of 2015

2016 · first_quarter · Firm: LYMPHOMA RESEARCH FOUNDATION

Open original LDA filing ↗

Cited source text and reported amounts

Cancer Drug Parity Act of 2015 (H.R. 2739/ S. 1566) Department of Defense Peer Reviewed Cancer Research Program

Client expense: $6,199 · Firm income: —

Matched citations: S. 1566

H.R. 2739114th Congress

Cancer Drug Coverage Parity Act of 2015

2015 · fourth_quarter · Firm: LYMPHOMA RESEARCH FOUNDATION

Open original LDA filing ↗

Cited source text and reported amounts

Cancer Drug Parity Act of 2015 (H.R. 2739/ S. 1566) Department of Defense Peer Reviewed Cancer Research Program

Client expense: — · Firm income: —

Matched citations: H.R. 2739

H.R. 2846114th Congress

Planning Actively for Cancer Treatment (PACT) Act of 2015

2015 · fourth_quarter · Firm: LYMPHOMA RESEARCH FOUNDATION

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 2846 - Planning Actively for Cancer Treatment (PACT) Act.

Client expense: — · Firm income: —

Matched citations: H.R. 2846

S. 1566114th Congress

Cancer Drug Coverage Parity Act of 2015

2015 · fourth_quarter · Firm: LYMPHOMA RESEARCH FOUNDATION

Open original LDA filing ↗

Cited source text and reported amounts

Cancer Drug Parity Act of 2015 (H.R. 2739/ S. 1566) Department of Defense Peer Reviewed Cancer Research Program

Client expense: — · Firm income: —

Matched citations: S. 1566

H.R. 2739114th Congress

Cancer Drug Coverage Parity Act of 2015

2015 · third_quarter · Firm: LYMPHOMA RESEARCH FOUNDATION

Open original LDA filing ↗

Cited source text and reported amounts

Cancer Drug Parity Act of 2015 (H.R. 2739/ S. 1566)

Client expense: — · Firm income: —

Matched citations: H.R. 2739

H.R. 2846114th Congress

Planning Actively for Cancer Treatment (PACT) Act of 2015

2015 · third_quarter · Firm: LYMPHOMA RESEARCH FOUNDATION

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 2846 - Planning Actively for Cancer Treatment (PACT) Act.

Client expense: — · Firm income: —

Matched citations: H.R. 2846

S. 1566114th Congress

Cancer Drug Coverage Parity Act of 2015

2015 · third_quarter · Firm: LYMPHOMA RESEARCH FOUNDATION

Open original LDA filing ↗

Cited source text and reported amounts

Cancer Drug Parity Act of 2015 (H.R. 2739/ S. 1566)

Client expense: — · Firm income: —

Matched citations: S. 1566

H.R. 2846114th Congress

Planning Actively for Cancer Treatment (PACT) Act of 2015

2015 · second_quarter · Firm: TURNER & GOSS LLP

Open original LDA filing ↗

Cited source text and reported amounts

Planning Actively for Cancer Treatment (PACT) Act, HR 2846 and submission of comments to Senate Finance Committee in response to request for information on chronic care management in Medicare.

Client expense: — · Firm income: —

Matched citations: HR 2846

H.R. 2739114th Congress

Cancer Drug Coverage Parity Act of 2015

2015 · second_quarter · Firm: LYMPHOMA RESEARCH FOUNDATION

Open original LDA filing ↗

Cited source text and reported amounts

Cancer Drug Parity Act of 2015 (H.R. 2739/ S. 1566)

Client expense: — · Firm income: —

Matched citations: H.R. 2739

H.R. 2846114th Congress

Planning Actively for Cancer Treatment (PACT) Act of 2015

2015 · second_quarter · Firm: LYMPHOMA RESEARCH FOUNDATION

Open original LDA filing ↗

Cited source text and reported amounts

PACT Act (H.R. 2846) and Senate Finance Committee request for feedback on chronic care management in the Medicare Program.

Client expense: — · Firm income: —

Matched citations: H.R. 2846

S. 1566114th Congress

Cancer Drug Coverage Parity Act of 2015

2015 · second_quarter · Firm: LYMPHOMA RESEARCH FOUNDATION

Open original LDA filing ↗

Cited source text and reported amounts

Cancer Drug Parity Act of 2015 (H.R. 2739/ S. 1566)

Client expense: — · Firm income: —

Matched citations: S. 1566

Source: Senate LDA